SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
Manipulating the HIV Immune Response for Prevention and Treatment
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
10 of
10
|
Autologous Functional Antibody Dynamics in the Context of bNAb Therapy for HIV (ABSTRACT
166)
Boris Juelg
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Autologous Monoclonal Neutralizing Antibodies as a Promising Path to a Functional HIV-1 Cure (ABSTRACT
167)
Junlin Zhuo
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
In Vivo HSC Gene Therapy Drives Sustained eCD4-Ig Expression Primarily by B-Cells for SIV Prevention (ABSTRACT
168)
John K. Bui
Fred Hutchinson Cancer Center, Seattle, WA, USA
Shared Resistance Pathways to CD4bs bNAbs Between Viremic SHIV NHP Model and Human Clinical Trials (ABSTRACT
169)
Jiajie Li
University of Pennsylvania, Philadelphia, PA, USA
Questions and Answers (Part 1)
Assessing Early Immune Response to HIV Rebound in Viremic Controllers and Noncontrollers (ABSTRACT
170)
Anna Farrell-Sherman
Fred Hutchinson Cancer Center, Seattle, WA, USA
A Conserved NK-Like KIR+ CD8+ T-Cell Subset Mediates Exceptional HIV Control and Functional HBV Cure (ABSTRACT
171)
Gaurav Gaiha
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Innate Immune Imprints Shape HIV-1 Reservoir Cell Persistence During Long-Term ART (ABSTRACT
172)
Toong Seng Tan
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Repeated IL-10/PD-1 Blockades Potently Control SIV Rebound and Limit Reservoir in the Absence of ART (ABSTRACT
173)
Mirko Paiardini
Emory University, Atlanta, GA, USA
Questions and Answers (Part 2)
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
10 of
10
|
